Candidemia

The FDA recently approved Rezzayo, a weekly injectable treatment for adults with candidemia and invasive candidiasis.

The FDA approved rezafungin for injection to treat candidemia and invasive candidiasis in adults, offering a new treatment for people with limited or no other options.

The FDA Antimicrobial Drugs Advisory Committee voted on Wednesday 14-1 in favor of the use of rezafungin for the treatment of candidemia and invasive candidiasis.

Recurrent candidemia was reported in 6% of people with prior candidemia, with many patients reporting recent hospitalization, hepatitis C infection and being of younger age, according to a study published in Open Forum Infectious Diseases.

An analysis of U.S. surveillance data revealed that nearly 30% of patients with candidemia initially received fluconazole, resulting in potentially inappropriate treatment, researchers reported.

The investigational antifungal fosmanogepix was found to be safe and well tolerated with a high level of treatment success in patients with candidemia, according to data from a small open-label study presented at IDWeek.

A recent study demonstrated the safety and efficiency of drive-through testing for COVID-19. It was the top story in infectious disease last week.

Infectious disease consultation was associated with a 59% reduction in mortality among patients hospitalized with candidemia, according to the results of a systematic review and meta-analysis published in Open Forum Infectious Diseases.

Among patients with common bloodstream infections, lack of infectious disease consultation was associated with a more than fourfold increased hazard of death at 3 months, according to findings from a recently published study.

Surveillance data showed that more than 10% of candidemia cases in nine U.S. states in 2017 occurred in patients with a history of recent injection drug use, including more than 34% of cases in patients aged 19 to 44 years — an “unexpectedly high” proportion,” researchers reported.